香雪制药(300147) - 2025 Q1 - 季度财报

Financial Performance - Revenue for Q1 2025 was ¥421,004,187.88, a decrease of 25.99% compared to ¥568,856,745.84 in the same period last year[4] - Net profit attributable to shareholders was -¥87,732,945.81, representing a decline of 146.03% from -¥35,659,979.04 year-over-year[4] - The net cash flow from operating activities was -¥82,460,305.69, a significant drop of 419.44% compared to ¥25,813,931.15 in the previous year[4] - The basic and diluted earnings per share were both -¥0.13, a decline of 160.00% from -¥0.05 in the same period last year[4] - The weighted average return on equity was -8.68%, down 6.81% from -1.87% year-over-year[4] - Total operating revenue for the current period is ¥421,004,187.88, a decrease of 26.0% from ¥568,856,745.84 in the previous period[19] - The net profit for the current period is a loss of ¥80,072,625.44, compared to a loss of ¥28,629,807.17 in the previous period, representing an increase in loss of 179.5%[20] - The total comprehensive income for the current period is a loss of ¥80,115,222.89, compared to a loss of ¥28,625,879.70 in the previous period[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,443,659,743.86, a decrease of 0.73% from ¥7,498,398,859.64 at the end of the previous year[4] - The company's cash and cash equivalents decreased from ¥131,741,496.06 to ¥57,521,160.42, a decline of approximately 56.4%[16] - Accounts receivable increased from ¥810,129,690.20 to ¥908,036,996.48, representing a growth of about 12.1%[16] - Inventory decreased from ¥340,919,525.62 to ¥311,394,935.92, a reduction of approximately 8.7%[16] - Total current liabilities increased from ¥5,382,016,741.51 to ¥5,777,245,299.89, an increase of about 7.3%[17] - The company's total assets decreased from ¥7,498,398,859.64 to ¥7,443,659,743.86, a decline of approximately 0.7%[17] - The total equity attributable to shareholders decreased from ¥1,054,899,213.92 to ¥967,123,670.66, a decrease of about 8.3%[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 50,635[10] - The largest shareholder, Guangzhou Kunlun Investment Co., Ltd., held 22.59% of the shares, totaling 149,409,921 shares[10] Government and Regulatory Matters - The company reported a government subsidy of ¥1,202,742.95 during the period[5] - The company has not yet received a formal administrative penalty decision from the regulatory authority regarding the previous non-operating fund occupation[12] Operational Changes - The company has completed the repayment of non-operating funds occupied by the controlling shareholder, totaling ¥3,679,200.00, through a debt offset arrangement[12] - The company is currently undergoing a pre-restructuring process with appointed temporary managers to oversee the proceedings[14] - The company reported a significant increase in accounts receivable financing from ¥7,747,175.19 to ¥1,089,738.65, indicating a shift in financing strategy[16] Expenses - Total operating costs for the current period are ¥484,017,651.17, down 18.1% from ¥591,588,915.65 in the previous period[19] - Research and development expenses for the current period are ¥15,977,095.47, a decrease of 7.8% from ¥17,327,643.17 in the previous period[19] - The company incurred a credit impairment loss of ¥1,241,310.64, compared to a loss of ¥568,029.24 in the previous period[20] Audit Status - The company has not yet audited the first quarter report for the current year[25]